3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
36
Gastrointestinal
36
Endocrine
36
Thoracic
3
Head & Neck
2
Breast
2
Sarcoma
1
Other solid neoplasm
1
Gynecologic
1
Genitourinary
1
Dermatologic
1
Conditions
Ovarian Neoplasms
1773
Uterine Cervical Neoplasms
1499
Endometrial Neoplasms
833
Breast Neoplasms
434
Carcinoma, Ovarian Epithelial
405
Fallopian Tube Neoplasms
399
Uterine Cervical Dysplasia
276
Neoplasms
252
Colorectal Neoplasms
179
Uterine Neoplasms
173
Peritoneal Neoplasms
170
Vulvar Neoplasms
155
Lung Neoplasms
150
Pancreatic Neoplasms
141
Prostatic Neoplasms
135
Recurrence
128
Stomach Neoplasms
126
Colonic Neoplasms
116
Papillomavirus Infections
115
Melanoma
101
Sarcoma
97
Urinary Bladder Neoplasms
95
Vaginal Neoplasms
93
Carcinoma, Non-Small-Cell Lung
92
Head and Neck Neoplasms
91
Neoplasm Metastasis
83
Esophageal Neoplasms
82
Testicular Neoplasms
80
Rectal Neoplasms
71
Kidney Neoplasms
62
Interventions
zimberelimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Gastro-enteropancreatic neuroendocrine tumor
×
Gynecologic
×
Clear all
NCT06790706
2025-10-06
IMMUNORARE5
Hospices Civils de Lyon
Phase 2
Recruiting
154 enrolled